A deep dive into the sector breakdowns, media sentiment analysis, and contrarian positioning that drove the BTM portfolio's exceptional performance.
Materials – Gold & Precious Metals
At entry (mid-2021), gold was out of favor amid a booming stock market. By 2022-2023, surging inflation and the Russia-Ukraine war renewed interest in gold as a safe haven. By 2024, sentiment turned outright bullish as gold approached record highs of ~$2,700/oz.
Gold prices climbed to all-time highs. 2022 and 2023 saw unprecedented central bank buying – the two largest years ever for official gold purchases. Geopolitical tensions led to de-dollarization discussions and BRICS expansion.
Entering gold positions in mid-2021 was a contrarian bet. Prevailing sentiment favored risk assets over precious metals, and inflation was thought to be "transitory." This contrarian stance proved prescient as the narrative flipped in gold's favor.
Materials – Rare Earth Elements
Sentiment was mixed. Governments emphasized the critical importance of rare earths for supply chain security. However, by 2023-2024, prices declined due to rising Chinese exports, dampening investor enthusiasm despite the strategic narrative.
Lynas secured DoD funding to build a heavy rare earth separation facility in Texas. MP Materials received government grants to develop processing capabilities. These were breakthroughs in establishing domestic rare earth supply chains.
Investing in rare earth companies was somewhat contrarian. While the geopolitical case was strong, market sentiment had cooled along with broader tech/battery metals hype. The bet was that strategic necessity would eventually outweigh temporary pessimism.
Energy – Oil & Gas E&P, Services, Power Generation
The portfolio repeatedly moved into energy when sentiment was negative. Magnolia's mid-2020 entry came just after the historic oil price crash – WTI briefly went negative. That contrarian entry preceded a huge rebound as oil hit record highs by late 2021.
Wild swings from collapse in 2020 to >$100/barrel in 2022 amid the Ukraine war. Talen Energy emerged from bankruptcy and relisted, joining the S&P 400. Companies generated record cash flows by 2022.
Buying oil stocks in mid-2020 when few dared was a classic contrarian bet. Talen was purchased right after emerging from Chapter 11 – an undervalued new listing that many avoid. The portfolio repeatedly took the other side of fear.
Industrials – Defense Contractors, Aerospace
The Russian invasion of Ukraine in Feb 2022 was a game-changer. Europe's defense sector doubled in value in the first year after the invasion. Media coverage highlighted increased budgets, wartime demand, and sustained military spending.
AeroVironment saw a surge in orders as drones proved vital in Ukraine. Aerojet Rocketdyne was acquired by L3Harris at a premium. Elbit and others benefited from record order backlogs as NATO countries rearmed.
Initial moves into defense (2021–early 2022) were contrarian because the sector had been neglected. Those early entries proved timely. Later positions (like KTOS in 2024) focused on smaller, less-proven companies in an already-hot sector.
Technology – Social/Media, Enterprise Software, AI/Big Data, Fintech, Space
Tech went through a boom-bust-boom cycle. By late 2021, rising rates caused a severe selloff. The Nasdaq dropped ~33% in 2022. By 2023, the "AI boom" ignited a tech recovery with stocks like Palantir and C3.ai becoming market darlings.
Meta underwent a dramatic turnaround – cost cuts and AI pivot led to a huge stock rebound. Palantir announced first profitable quarters. Splunk was acquired by Cisco for ~$28 billion. C3.ai rallied on AI software potential.
Buying Meta right after its historic crash, or accumulating chip names during downturns – all went against prevailing negative sentiment. The willingness to hold through deep drawdowns also stands out.
Healthcare – Biotechnology, Pharma, Healthcare Services
Biotech experienced a significant downturn in 2021-2022 after the 2020 boom. Media dubbed it a "biotech winter." This pessimism created a contrarian opportunity. Coverage improved by 2023 as major acquisitions occurred.
ImmunoGen secured FDA approval for its ovarian cancer drug. Apellis got eye disease treatment approval. Mirati was acquired by Bristol-Myers Squibb for ~$5.8B. ChemoCentryx was bought by Amgen.
Buying when few others would – accumulating positions in select names despite prevailing gloom. By late 2021-2022, many small biotechs had fallen 60-80% from highs. This was classic contrarian investing.
Consumer Discretionary & Staples, Financial Services
Consumer stocks saw shifting sentiment. In mid-2022, LULU and ULTA were added during recession fears. Financials swung with macro events. Schwab was added in March 2023 right into the regional banking crisis panic.
Lululemon and Ulta reached all-time highs by 2023. Coty doubled from 2020 lows after successful relaunches. Schwab rebounded after deposit flight fears proved overblown.
Schwab in the bank panic of 2023 was textbook contrarian buying. Coty in 2020 was a beaten-down "COVID loser." The fund consistently looked for quality businesses experiencing short-term setbacks.
Across this diverse set of trades, several key themes emerge that define the BTM investment philosophy.
Nearly all trades were initiated at times when the target stock or sector was facing skepticism, distress, or apathy. The portfolio bought oil in 2020 when it went negative, gold in 2021 when inflation fears were minimal, tech in 2022 when NASDAQ was in freefall, and banks during the 2023 crisis.
Trades anticipated specific catalysts: geopolitical conflict (gold, defense), technological breakthroughs (AI, quantum, space), healthcare catalysts (FDA approvals, M&A), and post-crisis recoveries (banks, energy, travel).
Many trades were held for 1-3+ years rather than quick flips. The investor often entered early, well before the crowd, and was willing to wait for sentiment to turn or catalysts to materialize.
A noticeable concentration in Energy, Materials, and Industrials suggests a macro perspective favoring tangible assets during a time of inflation and global unrest. This proved largely accurate.
Just as entries were contrarian, exits were often timed when the thesis had been proven. Gold plays were sold as gold hit highs. Meta and Palantir were sold after huge 2023 runups.
The entire set of trades reflects a coherent philosophy: identify areas that are unloved but poised for a positive change, invest in a basket of opportunities there, and wait for the rest of the world to catch on.
The recurring sectors (commodities, defense, innovative tech, biotech) all had periods of extreme pessimism that the portfolio turned into opportunity. Repeatedly, we see "contrarian bets" that the consensus was wrong – and in many cases, a notable catalyst proved the bet right.
This consistency in approach – contrarian, catalyst-focused, and theme-driven – is the key unifying pattern across all trades.
"Buy low, sell high" writ large – executed not randomly but in areas with clear potential catalysts and often against the prevailing grain.